This article is more than 5 years old. Information may no longer be current.

Zimmer and ISTO Technologies announce phase III clinical trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Zimmer Holdings, Inc. and ISTO Technologies, Inc. announced the launch of a Phase III clinical trial to evaluate the DeNovo ET Engineered Tissue Graft at the American Academy of Orthopedics Surgeon annual meeting in San Francisco.

The DeNovo ET Graft is an engineered juvenile cartilage implant intended to repair cartilage defects in the knee, and it is being developed under a collaborative relationship between Zimmer and ISTO, according to a Zimmer release. The study will comprise a randomized, controlled clinical trial involving 225 patients in up to 25 centers in the U.S.

“The DeNovo ET Graft program represents a natural extension to our early intervention and joint preservation portfolio,” Cheryl R. Blanchard, PhD, senior vice president and chief scientific officer at Zimmer, stated in the release. “This Phase III study will generate meaningful data on the potential of this novel biological solution for treatment of cartilage lesions earlier in the continuum of care.”